Medical Marijuanaの出資会社がCanChew Plusガムによる過敏性腸症候群治療の臨床試験

AsiaNet 67714（0344）

【ニューヨーク2017年3月8日PR Newswire＝共同通信JBN】米国で初めての大麻公然取引会社であるMedical Marijuana, Inc.（http://medicalmarijuanainc.com/ ）（OTC: MJNA）は8日、同社の主要出資会社であるAXIM（R）Biotechnologies, Inc.（AXIM（R）Biotech）（http://aximbiotech.com/ ）（AXIM）（http://finance.yahoo.com/q?s=axim ）が40人の患者を募集し、同社のCanChew Plus（R）CBDガムによる過敏性腸症候群（IBS）治療の第II相臨床試験を開始したと発表した。この研究はオランダ・ワーゲニンゲン大学のレンゲル・ウィトカンプ教授兼栄養・薬理学主任が実施する。

約400人の患者プールから選ばれた18歳から65歳の40人の患者は8週間の無作為、ダブルブラインドのクロスオーバー試験の対象となる。患者はCanChewチューインガムの場合はガム1個当たり50mg大麻を含むチューインガムまたはにせもののチューインガムを毎日最大6個受け取る。

主要結果判定のための最終的なデータ収集は2017年4月に完了の見込みで、研究全体の完了は2017年6月の見込みである。

Medical Marijuana, Incのステュアート・タイタス最高経営責任者（CEO）は「IBS治療におけるカンナビノイド研究の医学史上初めての進展を示すこのIBS臨床試験で患者募集に成功したことは、AXIMの臨床開発プログラムのエキサイティングな新マイルストーンである。IBSの治療市場は2023年までに15億ドルまで成長すると見込まれており、IBSだけでなく過敏性腸疾患、潰瘍性大腸炎など最も一般的な胃腸障害に苦しむ人々を助ける先端的なソリューションを前進させるAXIMの努力は続く」と語っている。

AXIMのIBS試験についての詳しい情報はhttps://clinicaltrials.gov/ct2/show/NCT03003260 へ。

IBSは最も一般的な機能性の胃腸障害であり、世界の罹患率は9-23%で米国での通院全体の約12%を占めている。この病気は生命を脅かすものではないが、生活の質をひどく傷つけるし、IBSにはこれまでのところ治癒や真の治療法はない。この研究の目的はCBDを含むCanChew Plusチューインガムの利用がIBSの症状軽減と患者の福利への影響の改善に貢献できるかどうかを調べることである。

▽AXIM（R）について

AXIM Biotechnologies, Inc.は大麻ベースの医薬、栄養、化粧製品の研究。開発、製造に集中している。同社の主力製品はCBSベースの制御リリース・チューインガムのCanChew PlusとMedChew Rx（R）が含まれており、結合CBD/THCガムは多発性硬化症に伴う痛みと痙縮の治療用に臨床試験が行われる。AXIMは堅実な財政戦略をとり、顧客の福利を優先している。Medical Marijuana, IncはAXIMへの主要な出資会社である。詳しい情報はwww.AXIMBiotech.com へ。

▽Medical Marijuana, Incについて

Medical Marijuanaの使命は一流の大麻会社、大麻業界の革新会社にあることであり、専門家チームを活用して付加価値企業、製品を探し出し、評価、買収しながらこれら企業がそのまま存在し、起業精神を持ち続けられるようにすることである。同社は自らの業界への理解をつくり出し、環境にやさしく、経済的に持続可能な企業を発展させる一方で株主の価値を増大させるために努力している。Medical Marijuana, Incのポートフォリオ、出資会社の詳細はwww.medicalmarijuanainc.com へ。

Medical Marijuana, Incのビデオ声明を見るには（https://www.youtube.com/watch?v=hidd8sa-eVQ ）をクリックすること。株主には割引製品のためにMedical Marijuana, Incショップ（http://medicalmarijuanainc.com/store/ ）も訪れるよう勧める。

▽問い合わせ先

PR問い合わせ先:

Andrew Hard

Chief Executive Officer

CMW Media

P. +1 888-829- 0070

andrew.hard@cmwmedia.com

www.cmwmedia.com

ソース：Medical Marijuana, Inc.

Medical Marijuana, Inc. Investment AXIM(R) Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome (IBS) With CanChew Plus(R) Cannabidiol (CBD) Chewing Gum

PR67714

NEW YORK, March 8, 2017 /PRNewswire=KYODO JBN/ --

Medical Marijuana, Inc. (http://medicalmarijuanainc.com/ ) (OTC: MJNA), the

first-ever publicly traded cannabis company in the United States, announced

today that its major investment company AXIM(R) Biotechnologies, Inc. (AXIM(R)

Biotech) (http://aximbiotech.com/ ) (AXIM) (http://finance.yahoo.com/q?s=axim )

has enrolled 40 patients and commenced its Phase II clinical trial for the

treatment of irritable bowel syndrome (IBS) with the company's CanChew Plus(R)

CBD gum. The study is being conducted by Renger Witkamp, Professor and Chair in

Nutrition and Pharmacology, at Wageningen University in the Netherlands.

Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be

subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients

will receive a maximum 6 chewing gums per day, either containing 50 mg of

cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo

chewing gum.

Final data collection for primary outcome measure is estimated to complete in

April 2017, with the full study estimated to complete in June 2017.

"Successfully enrolling patients in this IBS clinical trial, which marks the

first advancement in cannabinoid research for treatment of IBS in medical

history, is an exciting new milestone for AXIM's clinical development program,"

said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "With the global treatment

market for IBS estimated to grow in value to $1.5 billion by 2023, AXIM's

efforts continue to push forward with cutting-edge solutions to help people

suffering from some of the most common gastrointestinal disorders, not only for

IBS, but for Irritable Bowel Disease and Ulcerative Colitis as well."

For more information on the AXIM's IBS trial, please visit:

https://clinicaltrials.gov/ct2/show/NCT03003260

IBS is the most common functional gastrointestinal disorder with a prevalence

worldwide ranging from 9-23% and results in around 12% of all physician visits

in US. Although the condition is not life-threatening, it strongly impairs

quality of life and up to now there is no cure or real treatment for IBS. The

objective of the study is to investigate whether the use of a CBD-containing

CanChew Plus(R) chewing gum can contribute to a reduction of IBS symptoms and

an improvement of perceived patients' wellbeing.

About AXIM(R)

AXIM(R) Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development

and production of cannabis-based pharmaceutical, nutraceutical and cosmetic

products. Its flagship products include CanChew Plus(R), a CBD-based controlled

release chewing gum, and MedChew Rx(R); a combination CBD/THC gum that will be

undergoing clinical trials for the treatment of pain and spasticity associated

with multiple sclerosis. AXIM prioritizes the well-being of its customers while

embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor

in AXIM. For more information, please visit www.AXIMBiotech.com.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators,

leveraging our team of professionals to source, evaluate and purchase

value-added companies and products, while allowing them to keep their integrity

and entrepreneurial spirit. We strive to create awareness within our industry,

develop environmentally-friendly, economically sustainable businesses, while

increasing shareholder value. For details on Medical Marijuana, Inc.'s

portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here

(https://www.youtube.com/watch?v=hidd8sa-eVQ ). Shareholders are also

encouraged to visit the Medical Marijuana, Inc. Shop

(http://medicalmarijuanainc.com/store/ ) for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES

This press release may contain certain forward-looking statements and

information, as defined within the meaning of Section 27A of the Securities Act

of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject

to the Safe Harbor created by those sections. This material contains statements

about expected future events and/or financial results that are forward-looking

in nature and subject to risks and uncertainties. Such forward-looking

statements by definition involve risks, uncertainties. The statements in this

press release have not been evaluated by the FDA and are not intended to

diagnose, treat or cure any disease. The Company does not sell or distribute

any products that are in violation of the United States Controlled Substances

Act. The Company does sell and distribute hemp-based products.

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. +1 888-829- 0070

andrew.hard@cmwmedia.com

www.cmwmedia.com

SOURCE Medical Marijuana, Inc.